GlassScriptPhysician profile
James Scott Warren
NPI 1073931234
$5,735.70
in general payments reported to CMS, 2019-2025
26 companies · $842 in 2025
The $842 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $296 · 2021: $1,087 · 2022: $777 · 2023: $1,229 · 2024: $1,505 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,575.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $831.17 | 2021-2025 | Teflaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $670.44 | 2020-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $655.41 | 2020-2024 | Xarelto |
| Gilead Sciences, INC. | $601.78 | 2021-2025 | Veklury |
| Pfizer INC. | $397.92 | 2020-2025 | |
| Boston Scientific Corporation | $302.92 | 2020-2025 | Watchman Flx, Watchman, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $287.78 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $286.01 | 2020-2025 | Zerbaxa, Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.96 | 2020-2025 | Xifaxan |
| Stimwave Technologies Incorporated | $248.14 | 2021 | |
| Paratek Pharmaceuticals, INC. | $221.84 | 2021-2024 | Nuzyra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $208.20 | 2020-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $136.44 | 2022-2024 | Givlaari |
| Alexion Pharmaceuticals, INC. | $121.75 | 2021-2023 | Ultomiris |
| Philips North America LLC | $95.28 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $85.53 | 2021-2023 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $62.91 | 2020-2025 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $54.94 | 2022-2024 | Eliquis |
| Scpharmaceuticals INC. | $40.99 | 2025 | |
| Glaxosmithkline, LLC. | $35.80 | 2025 | Trelegy Ellipta |
| Inari Medical, INC. | $28.06 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cmp Pharma, INC. | $23.16 | 2021 | |
| Abbott Laboratories | $22.20 | 2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $21.36 | 2025 | |
| Kestra Medical Technology Services, INC. | $18.99 | 2024 | Assure Wcd |
| Takeda Pharmaceuticals U.S.A., INC. | $15.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.